Page 153 - 南京医科大学自然版

第45卷第8期 刘雨清，马 玲，束永前. 产甲胎蛋白胃癌生物学特征及治疗策略的研究进展［J］.
2025年8月 南京医科大学学报（自然科学版），2025，45（8）：1202-1210 ·1209 ·

represents fetal gut differentiation of gastric cancer，and ［42］HAYASHI K，NAGASAKI E，NAKADA K，et al. Chemo⁃
is diagnostically useful in distinguishing hepatoid gastric therapy for alpha⁃fetoprotein producing gastric cancers ex⁃
carcinoma from hepatocellular carcinoma［J］. Am J Surg pressing human epidermal growth factor receptor 2［J］. J
Pathol，2010，34（4）：533 Infect Chemother，2018，24（4）：298-301
［33］IKEDA H，SATO Y，YONEDA N，et al. α⁃Fetoprotein⁃pro⁃ ［43］KAMIIMABEPPU D，WAKATSUKI T，TAKAHARI D，et
ducing gastric carcinoma and combined hepatocellular al. Treatment efficacy of ramucirumab⁃containing chemo⁃
and cholangiocarcinoma show similar morphology but dif⁃ therapy in patients with alpha⁃fetoprotein producing gas⁃
ferent histogenesis with respect to SALL4 expression［J］. tric cancer［J］. Int J Clin Oncol，2023，28（1）：121-129
Hum Pathol，2012，43（11）：1955-1963 ［44］ARAKAWA Y，TAMURA M，AIBA K，et al. Significant
［34］WANG B，XIE Y，ZHENG L，et al. Both the serum AFP response to ramucirumab monotherapy in chemotherapy⁃
test and AFP/GPC3/SALL4 immunohistochemistry are resistant recurrent alphafetoproteinproducing gastric can⁃
beneficial for predicting the prognosis of gastric adenocar⁃ cer：a case report［J］. Oncol Lett，2017，14（3）：3039-
cinoma［J］. BMC Gastroenterology，2021，21：408 3042
［35］YOSHIDA K，YASUFUKU I，TERASHIMA M，et al. In⁃ ［45］LI N，BAI C，ZHANG R，et al. Efficacy and safety of apa⁃
ternational retrospective cohort study of conversion thera⁃ tinib for the treatment of AFP⁃producing gastric cancer［J］.
py for stage Ⅳ gastric cancer 1（CONVO⁃GC⁃1）［J］. Ann Transl Oncol，2020，14（2）：101004
Gastroenterol Surg，2021，6（2）：227-240 ［46］DING X，DING J. Effective treatment of apatinib for che⁃
［36］YU P，PENGFEI Y，JIANG Z，et al. Comparison of surgi⁃ motherapyrefractory advanced gastric carcinoma with
cal resection combined with chemotherapy and palliative AFP secretion and HER2 positivity：a case report［J］. Mol
chemotherapy for synchronous hepatic metastases from Clin Oncol，2021，15（2）：1-5
gastric cancer.［J］. J Clin Oncol，2022，40：e16041- ［47］SONG F，HU B，CHENG J W，et al. Anlotinib suppresses
e16041 tumor progression via blocking the VEGFR2/PI3K/AKT
［37］TAKAHASHI K，TERASHIMA M，NOTSU A，et al. Surgi⁃ cascade in intrahepatic cholangiocarcinoma［J］. Cell
cal treatment for liver metastasis from gastric cancer：a Death Dis，2020，11（7）：573
systematic review and meta ⁃ analysis of long ⁃ term out⁃ ［48］ZHOU C，WANG W，MU Y，et al. Efficacy and safety of a
comes and prognostic factors［J］. Eur J Surg Oncol，2024， novel TKI（anlotinib）for the treatment of advanced diges⁃
50（10）：108582 tive system neoplasms：a systematic review and meta⁃anal⁃
［38］WU J W，ZHOU C F，HAN Z X，et al. Anlotinib plus che⁃ ysis［J］. Front Immunol，2024，15：1393404
motherapy as a first⁃line treatment for gastrointestinal can⁃ ［49］KATO K，XU R H，OH D Y，et al. 131MO tislelizumab
cer patients with unresectable liver metastases：a multico⁃ （TIS）plus chemotherapy（Chemo）vs placebo（PBO）plus
hort，multicenter，exploratory trial［J］. Signal Transduct chemo as first⁃line（1L）treatment of advanced gastric or
Target Ther，2024，9：344 gastroesophageal junction adenocarcinoma（GC/GEJC）：
［39］KAMATA S，KISHIMOTO T，KOBAYASHI S，et al. Possi⁃ patient reported outcomes（PRO）in the Asian subgroup of
ble involvement of persistent activity of the mammalian the RATIONALE ⁃ 305 study［J］. Ann Oncol，2024，35：
target of rapamycin pathway in the cisplatin resistance of S1456
AFP⁃producing gastric cancer cells［J］. Cancer Biol Ther， ［50］SHEN L，BAI Y，LIN X，et al. First⁃line（1L）nivolumab
2007，6（7）：1036-1043 （NIVO）plus chemotherapy（chemo）vs chemo in patients
［40］梅彦侠，李 明，文继航，等. 产甲胎蛋白型胃癌中甲胎 （pts）with advanced gastric cancer，gastroesophageal junc⁃
蛋白表达的调控机制及其与肿瘤细胞恶性生物学行为 tion cancer，and esophageal adenocarcinoma（GC/GEJC/
的关系［J］. 实用肿瘤杂志，2023，38（6）：528-536 EAC）：5⁃year（y）follow⁃up of Chinese pts from Check⁃
MEI Y X，LI M，WEN J H，et al. Regulatory mechanism Mate 649［J］. J Clin Oncol，2025，43（4_suppl）：392
of alpha ⁃ fetoprotein expression and its relationship with ［51］LI W，LI Q，YU Y，et al. Effect of immune checkpoint in⁃
malignant biological behavior in AFP ⁃ producing gastric hibitors plus chemotherapy on advanced gastric cancer pa⁃
cancer［J］. Journal of Practical Oncology，2023，38（6）： tients with elevated serum AFP or hepatoid adenocarcino⁃

528-536 ma［J］. Cancer Manag Res，2020，12：11113-11119
［41］GRIEB B C，AGARWAL R. HER2⁃directed therapy in ad⁃ ［52］XIANG J，GONG W，WANG C，et al. Complete remission
vanced gastric and gastroesophageal adenocarcinoma：tri⁃ of alpha ⁃ fetoprotein ⁃ producing gastric cancer by com⁃
umphs and troubles［J］. Curr Treat Options Oncol，2021， bined tislelizumab ⁃ apatinib treatment of a patient with
22（10）：88 proficient mismatch repair：a case report［J］. World J